Clinical Trial Finder

• -

  INCLUSION CRITERIA:

  In order to be eligible to participate in this study, an individual must meet all of the following criteria: - Adult patients (18 years and older) - Confirmed biochemical diagnosis of Cushing s disease (primary or recurrent) as evidenced by increased 24-hour urine free cortisol (UFC), normal or increased morning plasma Adrenocorticotropic Hormone (ACTH), and pituitary origin of excess ACTH.

• - Surgical candidate for resection of ACTH producing pituitary adenoma.

• - Enrolled in 03-N-0164, Evaluation of Neurosurgical Disorders.

• - Able to provide written informed consent at the time of study enrollment.

• - Participants who are physically able to become pregnant must use an effective form of birth control from 14 days prior to enrollment through 6 months following the last dose of vorinostat.

Participants who are able to father a child must use an effective form of birth control from Day 0 through 3 months following the last dose of vorinostat.

EXCLUSION CRITERIA:

• - Patients who have been previously treated with vorinostat.

• - Patients who have received sellar radiation.

• - Significant medical illnesses that in the investigator s opinion cannot be adequately controlled or would compromise the patient s ability to tolerate this vorinostat.

• - Any history of cancer, unless in complete remission and off of all therapy for that disease for a minimum of 3 years.

• - History of thromboembolic disorder or deep vein thrombosis.

• - Presence of abnormal hematological and biochemical parameters, (such as anemia or thrombocytopenia) as defined as: - Neutrophil count < 1.5 K//micro L.

• - Hemoglobin < 8.0 g/dL.

• - Hematocrit < 0.75x LLN (lower limit of normal) - RBC count < 0.75x LLN.

• - Platelet count < 100 x 10^3 cells/micro L.

• - Prothrombin time-international normalized ratio (PT-INR) > 1.5x ULN or Activated partial thromboplastin time (aPTT) > 1.5x ULN, with the exception of patients on prophylactic anticoagulation therapy.

• - Serum bilirubin level > 1.5x ULN.

• - Active infection being currently treated with systemic antibiotics.

• - Serious concurrent medical illness including renal failure (creatinine >3.0x - 6.0x ULN) liver failure (ALT/AST >5.0x - 20.0x ULN) or severe cardio-respiratory disease.

• - Pregnancy or lactation.

• - Presence of any disease that will obscure toxicity or dangerously alter drug metabolism (such as uncontrolled diabetes or bleeding disorders) - Currently receiving other investigational agents.

• - History of allergic reactions attributed to compounds of similar chemical or biologic composition to vorinostat, such as valproate.

• - Currently taking another HDACi, such as valproate.

• - Currently taking coumadin or its derivative anticoagulants.

- Currently taking any other medication to reduce cortisol or ACTH levels

Study Description. This is a single center, prospective pilot study of effectiveness of vorinostat to reduce midnight ACTH levels in patients with Cushing s Disease. Surgery for resection of ACTH producing pituitary adenoma will be offered at the NIH under another protocol (03-N-0164) as part of standard clinical care. Eligible subjects will be admitted to the Clinical Center for one week prior to surgery, during which time oral vorinostat will be administered daily. Objectives. Cushing s disease is caused by excess ACTH hormone release by a benign tumor of the pituitary gland. The resulting increase in cortisol levels caused by increased ACTH causes a severe condition that leads to decreased quality of life and early death. The current best first treatment for Cushing s disease is surgery. However, if surgery is unsuccessful or if the tumor returns, there are no good treatment options for patients. In laboratory studies, we discovered that a previously FDA approved oral medication Vorinostat was able to kill tumors cells and reduce ACTH secretion. We want to test whether this drug can be used in patients with Cushing s disease to reduce ACTH levels. Primary Objective: to determine whether vorinostat reduces midnight plasma ACTH level. Secondary Objectives: to evaluate the effect of vorinostat on urine cortisol levels. Endpoints. Primary Endpoint: midnight plasma ACTH level on the last day of drug administration. Secondary Endpoints: serum cortisol change during drug administration.

Arms

Experimental: single center, prospective pilot study

effectiveness of vorinostat to reduce midnight ACTH levels in patients with Cushing s Disease

Interventions

Drug: - Vorinostat

Administration of Vorinostat